SEC Form 4 · accession 0001144204-15-054457
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Avgerinos
Officer — SVP, Biologics Operations
Period of report
Sep 8, 2015
Accepted (ET)
Sep 10, 2015 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001F1 | Sep 8, 2015 | D | 11,704 | $2.5719 | D | 226,136 | D | |
| Common Stock, par value $0.001F2 | Sep 9, 2015 | D | 14,100 | $2.6199 | D | 212,036 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $2.55 to $2.63. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.
- F2This transaction was executed in multiple trades at prices ranging from $2.60 to $2.68. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.